VANCE LEAVES MEETING WITH TRUMP – DROPS EMERGENCY NEWS
Vance Sends HHS Gender-Medicine Billing Report to DOJ—But a Referral Is Not a Fraud Finding
In federal healthcare fraud cases, suspicious billing patterns can be enough to trigger an investigation.
They are not, by themselves, proof that a crime occurred.
That distinction is now at the center of a new move by Vice President JD Vance involving pediatric gender medicine and insurance billing.
Vance has referred a newly released Department of Health and Human Services report to Attorney General Todd Blanche and the Justice Department, asking federal law-enforcement officials to determine whether providers identified in the report violated federal law.
The report, titled “Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of ‘Gender Medicine,’” examines insurance coding, financial incentives and treatments including puberty blockers and cross-sex hormones provided to minors.
Vance’s message is considerably stronger than a request for a routine policy review.
If investigators determine that providers intentionally used false billing codes to obtain coverage that otherwise would not have been available, the vice president says criminal consequences should follow.
“When providers miscode treatment in order to secure insurance coverage for gender-transitioning interventions that insurance would not otherwise cover, they should be held accountable,” Vance wrote to Blanche.
“If they have done so intentionally, thereby perpetrating a fraud on Medicaid or on private insurers, they should go to prison,” he added.
The word “intentionally” is the key legal distinction.
HHS says its report identifies patterns that warrant scrutiny. The report does not establish that every flagged claim was false, that a provider knowingly submitted a false claim, or that any person committed a crime.
In fact, the report itself places an important limitation on its nationwide claims analysis: the results are described as “directional signals rather than findings” and require verification against the underlying medical records.
That makes the referral significant without making it a prosecution.
The numbers nevertheless explain why the administration is pressing the issue.
The HHS report says pediatric gender programs had expanded to more than 225 hospitals and health systems nationwide by the early 2020s.
Using nationwide medical claims data from 2015 through 2025, HHS said public and private insurers were billed nearly $50 million for puberty-blocking drugs for patients ages 9 through 17 on claims carrying endocrine-disorder diagnoses while excluding claims with gender-related or central precocious-puberty diagnoses.
The report says more than $40 million of that billing involved the code E34.9, “endocrine disorder, unspecified.”
HHS also highlighted a 2023 study involving 1,480 patients coded with that diagnosis.
“One study showed that only about 4.7 percent of patients diagnosed with ‘endocrine disorder, unspecified,’ had that actual condition,” Vance wrote.
He also cited a separate analysis discussed in the report that found a 30 percent increase in E34.9 diagnoses among minors between 2020 and 2022.
“Another notes a 30 percent increase in the number of endocrine disorder diagnoses, despite it being unlikely that there has been a substantial increase in pediatric endocrine disorders,” Vance continued.
HHS argues that those patterns may reflect the use of endocrine codes in cases involving gender-related treatment.
But the claims data alone do not answer the question investigators would ultimately have to resolve: whether a code was inaccurate, why it was used, and whether anyone knowingly used it to obtain improper payment.
The report identifies another category involving precocious-puberty coding.
HHS said its nationwide data showed nearly $11 million in billed charges for puberty blockers between 2015 and 2025 involving patients ages 13 through 17 whose claims carried a central precocious-puberty diagnosis.
The department focused on that age group because it says most patients are no longer treated for central precocious puberty with puberty blockers at those ages.
Again, HHS says the age values in its dataset are approximate and the results require verification against the underlying records.
Secretary Robert F. Kennedy Jr. has separately referred defined groups of claims to the HHS Office of Inspector General for investigation into possible violations of federal law.
That referral describes the claims as exhibiting “potentially anomalous billing patterns.”
One group includes puberty-blocker claims paired with endocrine-disorder diagnoses for patients ages 9 through 17 while excluding claims containing gender-related or central precocious-puberty diagnoses.
Another includes puberty-blocker claims carrying a central precocious-puberty diagnosis for patients ages 13 through 17.
A third covers claims from 2023 through 2026 involving a primary gender-dysphoria diagnosis and a cross-sex hormone prescription written the same day for a patient 17 or younger in a state where the procedure was prohibited for minors on the date of service.
Those referrals give investigators a defined set of transactions to examine rather than a general allegation against pediatric healthcare providers as a whole.
The report also makes a broader financial argument.
It cites data placing average annual healthcare costs for a child at roughly $3,000, then contrasts that with estimates of $25,000 to $75,000 in lifetime costs for certain gender-related treatment pathways without surgery.
When surgical interventions are added, the report says spending on surgeries can exceed $100,000 and approach $170,000.
Separately, HHS cites the Stop the Harm Database for nearly $120 million in submitted hospital and clinic charges involving minors since 2019, including more than 5,500 surgical procedures and approximately 8,500 courses of hormones or puberty blockers.
That distinction matters because the nearly $120 million figure is not the same dataset as HHS’s own nationwide claims analysis used for the $50 million and $11 million figures.
The administration argues that the amount of money involved creates incentives that deserve closer examination.
“Rather than allow the proliferation of harmful, sex-rejecting procedures on our children, we must send a clear message that any hospitals and providers that have participated in these practices will face justice,” Vance wrote.
But the Justice Department now has to answer a narrower question than the political language surrounding the report might suggest.
Federal fraud law does not turn every disputed diagnosis code into a criminal case.
Under the False Claims Act, liability can attach when a person knowingly submits or causes the submission of a false claim to the government. Criminal healthcare-fraud cases likewise require evidence sufficient to prove the elements of the charged offense, not simply an unusual billing pattern.
That is why Vance’s own formulation is conditional: if the miscoding was intentional and used to defraud Medicaid or private insurers, he says those responsible should go to prison.
The referral also arrives as the Trump administration is tightening federal policy around these treatments.
On August 11, HHS finalized a rule ending federal Medicaid and Children’s Health Insurance Program funding for the procedures covered by the rule for minors and young people. The rule is scheduled to take effect October 13, with a limited tapering period for some patients already receiving hormone therapy.
The billing report was released two days later.
Together, the actions show that the administration is pursuing the issue through both healthcare-financing rules and potential enforcement channels.
What they do not show is that DOJ has already concluded the providers identified by HHS committed fraud.
As of now, the Justice Department has not publicly announced criminal charges or prosecutions arising from Vance’s referral.
That leaves several possibilities open.
Investigators could find evidence that some claims were knowingly miscoded. They could identify civil violations without bringing criminal charges. They could determine that particular coding decisions had legitimate explanations. Or they could conclude that the available claims data are insufficient without additional medical and billing records.
The HHS report itself acknowledges why that verification step matters.
Claims databases can show what was billed. They do not automatically establish what a provider knew, why a particular code was selected or whether the underlying medical record supports it.
So Vance’s referral settles one issue: allegations that had been presented as a healthcare-policy and billing problem are now formally in the hands of the Justice Department.
What it does not settle is the central question on which any enforcement action would depend.
May you like
Were the flagged billing patterns errors, disputed coding practices or intentional false claims?
That is the difference between a report that raises suspicions and a case that can be proved—and it is now the question federal investigators have been asked to answer.
